Skip to content

Antiviral Therapies in the Management of Chronic Hepatitis C: The Present and the Future Pre-Test

Thank you for your interest in Boston University School of Medicine's program, "Antiviral Therapies in the Management of Chronic Hepatitis C: The Present and the Future". To help gauge audience knowledge, we would appreciate if you could complete this short pre-test. (All responses will be kept confidential)

If you have any questions, please contact our office (617-638-4605 or 800-688-2475 or cme@bu.edu).
1.Name:
2.Please create a personal code in the format the first 3 letters of your last name, birth month and birth day. (XXX/MM/DD) For example Mr. Smith, birth date of February 14 would be smi0214.
3.Please enter your email address to have a chance to win a Kindle Fire! (Completion of the pre-test will give you one entry in the draw)
4.Please enter your degree/credentials (i.e. MD, RN, NP)(Required.)
5.Which Hepatitis C conference location do you plan to attend?(Required.)
6.In treatment-naïve HCV patients initiated on boceprevir as part of a triple therapy regimen, which step do you take when early response is seen?(Required.)
7.A 51-year-old male former IV drug user with genotype 1 HCV, and a viral load of 2.4 million IU/ml, is started on triple therapy of PegIFN/ribavirin and telaprevir. When the patient returns in three weeks, what would be his most likely complaint in terms of side effects of this regimen? (Required.)
8.In terms of emerging combination therapy, daclatasvir in combination with which of the following, with or without ribavirin, showed sustained viral response at 24 weeks in genotype 1a/1b HCV? (Required.)
9.How confident would you be treating the following patient?
• 45-year-old male
• Genotype 1 HCV; viral load of 1.2 million IU/ml
• Labs:
− AST: 103
− ALT: 135
− ALP: 102
− T. bili: 1.1
− INR: 1.0
− ALB: 3.6
− WBC: 7.3
− HCT: 40.1
− PLT: 98
• Ultrasound: Coarse echotexture, lobular contour, no masses noted.
• Spleen: 13 cm
(Required.)
Not confident at all
Not very confident
Moderately confident
Confident
Very confident
10.A patient is on a triple therapy regimen of telaprevir + PegIFN/ribavirin. According to recommendations, you discontinue his telaprevir at 12 weeks. If the patient shows extended rapid viral response, how long would you continue him on PegIFN/ribavirin before discontinuing?(Required.)
11.According to recommendations, which of the following HCV genotypes would most benefit from IFN and ribavirin treatment? (Required.)
12.How confident are you at managing severe rash associated with telaprevir treatment? (Required.)
Not confident at all
Not very confident
Moderately confident
Confident
Very confident
13.A 35-year-old male with genotype 1 HCV is started on therapy. Boceprevir is added after 4 weeks. At eight weeks viral load is detectable. How long would you continue boceprevir treatment? (Required.)
14.In a patient taking telaprevir who presents with a mild localized rash with pruritis, which step do you currently take? (Required.)
15.How would you rate your knowledge of emerging therapies for HCV management? (Required.)
Very low
Low
Medium
High
Very high
16.In a patient who is taking sildenafil and needs to be started on telaprevir or boceprevir, how often do you discontinue sildenafil before initiating the HCV treatment? (Required.)
Never
Rarely
Sometimes
Usually
Always
17.While effective in many groups, triple therapy tends to be least effective in which group? (Required.)
18.Please rate your level of agreement with the following statement:
In a patient on telaprevir triple therapy who presents with a severe rash with vesicles and bullae, I discontinue telaprevir treatment (may or may not continue PegIFN/ribavirin)?(Required.)
Strongly disagree
Disagree
Neutral
Agree
Strongly agree
19.Compared to PegIFN/ribavirin therapy alone, triple therapy of boceprevir + PegIFN/ribavirin would be more likely associated with which adverse reaction? (Required.)
20.In which situation would you discontinue telaprevir treatment (may or may not continue treatment with PegIFN/ribavirin)? (Required.)
Thank you for your participation!